ANXA1 further appeared as a protective agent in Alzheimer’s disease by affecting amyloid-β clearance, following our recent report that ANXA1 reduced amyloid-β levels in vitro by increasing both microglial uptake and its enzymatic degradation in neurons.24 This evidence concerns the gene ANXA1 and early-onset autosomal dominant Alzheimer disease.